News archive
Showing 673 results
December 2008
-
Media ReleaseVideo: Gleevec Receives US Approval as First Treatment To Reduce Risk of Cancer Returning in Patients with Gastrointestinal Stromal TumorsUse of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many…
-
Media ReleaseVideo: Gleevec Receives US Approval as First Treatment To Reduce Risk of Cancer Returning in Patients with Gastrointestinal Stromal Tumors
-
Media ReleaseRAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial- RAD001 combined with Herceptin and chemotherapy in two separate Phase I trials halted tumor growth in 77% and 62% of patients, respectively- Novartis to start Phase III clinical trial program to…
-
Media ReleaseRAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
November 2008
-
Media ReleaseVideo: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'- Partnership aims to provide convenient access to vaccination - helping keep kids and teachers in school and parents at work- "Let's Fight Flu Together!" initiative supports CDC's new vaccination…
-
Media ReleaseVideo: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'
October 2008
-
Media ReleaseEarly Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment options have limited benefit for this debilitating, rapidly progressive and…
-
Media ReleaseEarly Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
September 2008
-
Media ReleaseRAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot- 77% of patients with pancreatic NET…
-
Media ReleaseRAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
-
Media ReleaseRAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland -- Data showing that RAD001 more than doubles time without tumor…
-
Media ReleaseRAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer